Financials in USD. Standardized financial statements.
A compact view of how Cipher Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $51.33M | $33.36M | $21.16M | $20.68M | $21.94M | $21.61M | $22.45M | $22.75M | $40.32M | $40.74M |
| Revenue Growth? | +53.9% | +57.7% | +2.4% | -5.8% | +1.6% | -3.8% | -1.3% | -43.6% | -1.0% | 0.0% |
| Cost of Revenue? | $17.56M | $9.26M | $4.07M | $3.99M | $3.68M | $3.06M | $2.91M | $2.31M | $1.90M | $4.59M |
| Gross Profit? | $33.77M | $24.10M | $17.09M | $16.68M | $18.26M | $18.55M | $19.55M | $20.44M | $38.42M | $36.15M |
| Gross Margin? | +65.8% | +72.2% | +80.8% | +80.7% | +83.2% | +85.9% | +87.1% | +89.8% | +95.3% | +88.7% |
| Operating Expenses? | $16.97M | $16.25M | $5.56M | $5.63M | $6.45M | $6.39M | $8.04M | $15.30M | $13.18M | $38.76M |
| Operating Income? | $16.80M | $7.85M | $11.53M | $11.09M | $11.82M | $12.20M | $11.68M | $5.33M | $25.24M | -$31.83M |
| EBITDA? | $16.80M | $11.87M | $11.53M | $11.95M | $13.66M | $13.40M | $12.87M | $4.61M | $21.09M | $14.43M |
| Income Before Tax | $17.46M | $2.96M | $12.68M | $11.48M | $11.06M | $6.54M | $5.71M | $3.12M | $14.27M | -$37.66M |
| Income Tax Expense | -$10.34M | -$8.59M | -$7.70M | -$15.16M | $3.30M | $2.15M | $3.07M | $1.92M | $3.52M | $1.49M |
| Net Income? | $27.81M | $11.54M | $20.38M | $26.64M | $7.76M | $4.55M | $3.24M | $543,000 | $4.28M | -$39.15M |
| EPS? | $1.09 | $0.47 | $0.82 | $1.01 | $0.29 | $0.18 | $0.12 | $0.02 | $0.16 | $-1.49 |
| Diluted EPS? | $1.07 | $0.46 | $0.80 | $0.99 | $0.29 | $0.18 | $0.12 | $0.02 | $0.16 | $-1.45 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality